The Impact of Metformin on Plasma Prolactin Levels in Antipsychotic-Treated Men With Hyperprolactinemia and Early-Onset Androgenic Alopecia

This review explores the risk factors, associated comorbidities, and psychological impacts of early-onset androgenetic alopecia, highlighting its complexity and potential implications for treatment response and overall health.

This study found that metformin's effect on reducing prolactin levels is less pronounced in women with PCOS compared to control subjects, likely due to higher endogenous testosterone levels, despite improvements in insulin sensitivity in both groups after six months of treatment.

This study found that men with early-onset androgenic alopecia are less responsive to the cardiometabolic effects of bromocriptine compared to men with normal hair growth.

This study suggests that metformin has a stronger impact on gonadotroph hormone levels in men with early-onset androgenic alopecia compared to those with normal hair growth.

This study found that metformin's metabolic benefits, such as reducing fat content and improving insulin sensitivity, were less pronounced in men with early-onset androgenic alopecia compared to those with normal hair growth, possibly due to differences in systemic inflammation and vitamin D status.

This review evaluates the hormonal, metabolic, and clinical aspects of a male equivalent PCOS syndrome in men and highlights areas where further research is needed, reporting no new empirical findings.

This review examines recent advances in understanding the pathophysiology and molecular mechanisms of androgenetic alopecia, highlighting two major genetic risk loci, but does not report new clinical findings.

This study suggests men with early androgenetic alopecia might have hormonal profiles similar to women with polycystic ovarian syndrome, potentially indicating risk for related health complications.

This article reviews recent advancements in understanding and treating androgenetic alopecia, focusing on new genetic insights, stem cell roles, and diagnostic tools, without reporting new clinical results.